Parkinson's disease, parkinsonism and aging

Archives of Gerontology and Geriatrics

Volumn 35, Issue SUPPL. 8, 2002, Pages 225-238

  Nicita Mauro, V ^a   Basile, G ^a   Mento, A ^a   Epifanio, A ^a   Martino, G ^a   Morgante, L ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

Frail elderly; Parkinson's disease; Parkinsonism and aging

Indexed keywords

APOMORPHINE; BROMOCRIPTINE; CABERGOLINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; DIHYDROERGOCRYPTINE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; DOPAMINE 5 RECEPTOR; ENTACAPONE; LEVODOPA; LISURIDE; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE; SELEGILINE; TOLCAPONE;

AGE; AGING; AUTONOMIC DYSFUNCTION; BODY POSTURE; BRADYKINESIA; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CONFERENCE PAPER; DELIRIUM; DEMENTIA; DEPRESSION; DIAGNOSTIC IMAGING; DISEASE COURSE; DOPAMINE BRAIN LEVEL; DRUG BIOAVAILABILITY; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HALLUCINATION; HUMAN; ILLUSION; INCIDENCE; LIVER DISEASE; MUSCLE RIGIDITY; NAUSEA; NERVE CELL DEGENERATION; ORTHOSTATIC HYPERTENSION; OXIDATIVE STRESS; PALLIDOTOMY; PARKINSON DISEASE; PARKINSONISM; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; RISK FACTOR; SEX DIFFERENCE; SURGICAL TECHNIQUE; SURVIVAL RATE; THALAMOTOMY; TREMOR; VOMITING;

EID: 0036993896     PISSN: 01674943     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-4943(02)00138-3     Document Type: Conference Paper

References (50)

1. Baker, M.G. (1999): Depression, psychosis, and dementia in Parkinson's disease: diagnosis and treatment. Neurology, 52 (Suppl. 3), S1 (Editorial).
2. Baldereschi, M., Di Carlo, A., Rocca, W.A., Vanni, P., Maggi, S., Perissinotto, E., Grigoletto, F., Amaducci, L. and Inzitari, D. (2000): Parkinson's disease and parkinsonism in a longitudinal study: two-fold higher incidence in men. ILSA Working Group. Italian Longitudinal Study on Aging. Neurology, 55, 1358-1363.
3. Ballard, P.A., Tetrud, J.W. and Langston, J.W. (1985): Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases. Neurology, 35, 949-956.
4. Bankiewicz, K.S., Leff, S.E., Nagy, D., Jungles, S., Rokovich, J., Spratt, K., Cohen, L., Libonati, M., Snyder, R.O. and Mandel, R.J. (1997): Practical aspects of the development of ex vivo and in vivo gene therapy for Parkinson's disease. Exp. Neurol., 144, 147-156.
5. Basile, G., Epifanio, A., Morgante, F., La Spina, P., Caronzolo, F., Martino, G., Di Rosa, A.E., Nicita-Mauro, V. and Morgante, L. (2001): Cognitive and mood disorders in elderly patients with Parkinson's disease. Arch. Gerontol. Geriatr., Suppl. 7, 33-36.
6. Benedetti, M.D., Bower, G.H., Maraganore, D.M., McDonnell, S.K., Peterson, B.J., Ahlskog, J.E., Schaid, D.J. and Rocca, W.A. (2000): Smoking, alcohol, and coffee consumption preceding Parkinson's disease. Neurology, 55, 1350-1358.
7. Bonifati, V., Breedveld, G.J., Squitieri, F., Vanacore, N., Brustenghi, P., Harhangi, B.S., Montagna, P., Cannella, M, Fabbrini, G., Rizzu, P., Van Duijn, C.M., Oostra, BA., Meco, G. and Heutink, P. (2002): Localization of autosomal recessive early-onset parkinsonism to chromosome 1p36 (PARK7) in an independent dataset. Ann. Neurol., 51, 253-256.
8. Chen, J.F., Xu, K., Petzer, J.P., Staal, R., Xu, Y.H., Beilstein, M., Sonsalla, P.K., Castagnoli, K., Castagnoli, N,jr. And Schwarzshild, M.A. (2001): Neuroprotection by caffeine and A (2A) adenosine receptor inactivation in a model of Parkinson's disease. J. Neurosci., 21, RC143.
9. Colosimo, C. and Antonini, A.. (2001): Malattia di Parkinson. In: Colosimo, C. (ed.): La malattia di parkinson e i disturbi del movimento. ClC-Edizioni Internazionali, Roma, (in Italian).
10. Cummings, J.L. (1992): Depression and Parkinson's disease: a review. Am. J. Psychiatr., 149, 443-454.
11. Di Rosa, A.E., Nicita-Mauro, V., Meduri, M. and Di Perri, R. (1987): Parkinsonism and flunarizine. Ital. J. Neurol. Sci., 1, 48.
12. Di Rosa, A.E., Morgante, L. and Nicita-Mauro, V. (1993): Malattia di Parkinson e sindromi parkinsoniane. In: Di Perri, R., Meduri, M. and Nicita-Mauro, V. (eds.): Neurogeriatria Oggi. Bios Publisher, Cosenza, pp.: 207-231 (in Italian).
13. Farrer, M., Gwinn-Hardy, K., Muenter, M., DeVrieze, F.W., Crook, R., Perez-Tur, J., Lincoln, S., Maraganore, D., Adler, C., Newman, S., MacElwee, K., McCarthy, P., Miller, C., Waters, C. and Hardy, J. (1999): A chromosome 4p haplotype segregating with Parkinson's disease and postural tremor. Hum. Mol. Genet., 8, 81-85.
14. Fearnley, J.M. and Lees, A.J. (1991): Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain, 114, 2283-2301.
15. Fowler, J.S. (1996): Inhibition of monoamine oxidase B in the brains of smokers. Nature, 379, 733-736.
16. Gasser, T., Muller-Myhsok, B., Wszolek, Z.K., Oehlmann, R., Calne, D.B., Bonifati, V., Bereznai, B., Fabrizio, E., Vieregge, P. and Horstmann, R.D. (1998): A susceptibility locus for Parkinson's disease maps to chromosome 2p13. Nat. Genet., 18, 262-265.
17. Gelb, D.J., Oliver, E. and Gilman, S. (1999): Diagnostic criteria for Parkinson Disease. Arch. Neurol., 56, 33-39.
18. Guttman, M. (1997): Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. International Pramipexole-Bromocriptine Study Group. Neurology, 49, 1060-1065.
19. Hornykiewicz, O. (1985). Brain dopamine and aging. Interdiscipl. Topics Gerontol. (Karger, Basel), 19, 143-151.
20. Jimenez-Jimenez, F.J., Mateo, D. and Gimenez-Roldan, S. (1992): Premorbid smoking, alcohol consumption, and coffee drinking habitus in Parkinson's disease: a case-control study. Mov. Disord., 7, 339-344.
21. Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, S., Minoshima, S., Yokochi, M., Mizuno, Y. and Shimizu, N. (1998): Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature, 392, 605-608.
22. Lang, A.E. (2000): Surgery of Parkinson disease. A critical evaluation of the state of the art. Arch. Neurol., 57, 1118-1125.
23. Lang, A.E. and Lozano, A.M. (1998a): Parkinson's disease. First of two parts. N. Engl. J. Med-. 339, 1044-1152.
24. Lang, A.E. and Lozano, A.M. (1998b): Parkinson's disease. Second of two parts. N. Engl. J. Med-. 339, 1130-1141.
25. Leroy, E., Boyer, R., Auburger, G., Leube, B., Ulm, G., Mezey, E., Harta, G., Brownstein, M.J., Jonnalagada, S., Chernova, T., Dehejia, A., Lavedan, C., Gasser, T., Steinbach, P.J., Wilkinson, K.D. and Polymeropoulos, M.H. (1998): The ubiquitin pathway in Parkinson's disease. Nature, 395, 451-452.
26. Limousin, P., Pollak, P., Benazzouz, A., Hoffmann, D., Le Bas, J.F., Brousolle, E., Perret, J.E. and Benabid, A.L. (1995): Effect on parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation. Lancet, 345, 91-95.
27. Maggio, R., Riva, M., Vaglini, F., Fornai, F., Molteni, R., Armogida, M., Racogni, G. and Corsini, G.V. (1998): Nicotine prevents experimental parkinsonism in rodents and induces striatal increase of neurotrophic factors. J. Neurochem., 71, 2439-2446.
28. Marsden, C.D. and Olanow, C.W. (1998): The causes of Parkinson's disease are being unraveled and rational neuroprotective therapy is close to reality. Ann. Neurol., 44 (Suppl. 1), S189-S196.
29. Mayeux, R., Chen, J., Mirabello, E., Marder, K., Bell, K., Dooneief, G., Cote, L. and Stern, Y. (1990): An estimate of the incidence of dementia in idiopathic Parkinson's disease. Neurology, 40, 1513-1517.
30. Morens, D.M., Grandinetti, A., Reed, D., White, L.R. and Ross, G.W. (1995): Cigarette smoking and protection from Parkinson's disease: False association or etiologic clue? Neurology, 45, 1041-1051.
31. Morgante, L., Rocca, W.A., Di Rosa, A.E., De Domenico, P., Grigoletto, F., Meneghini, F., Reggio, A., Savettieri, G., Castiglione, M.G., Patti, F. and Di Perri, R. (1992): Prevalence of Parkinson's disease and other types of parkinsonism: a door-to-door survey in three Sicilian municipalities. The Sicilian Neuro-Epidemiological Study (SNES) Group. Neurology, 42, 1901-1907.
32. Myllyla, V.V., Sotaniemi, K., Maki-Ikola, O., Rinne, U.K., and Heinonen, E.H. (1996): Role of selegiline in combination therapy of Parkinson's disease. Neurology; 47 (Suppl. 3), S200-S209.
33. Nicita-Mauro, V., Morgante, L, Venuto, P., Di Rosa, A.E. and Di Perri, R. (1985): Parkinsonismo iatrogeno nell'età senile. Giorn. Gerontol., 33, 1197 (in Italian).
34. Nutt, J.G. (1998): Cathecol-O-methyltransferase inhibitors for treatment of Parkinson's disease. Lancet, 351, 1221-1222.
35. Nutt, J.C. and Holford, N.H.G. (1996): The response to levodopa in Parkinson's disease: imposing pharmacological law and order. Ann. Neurol., 39, 561-573.
36. Olanow, C.W. (1997): A rationale for using dopamine agonists as primary symptomatic therapy in Parkinson's disease. In: Olanow, C.W. and Obeso, J.A. (eds.): Dopamine Agonists in Early Parkinson's Disease. Well Medical Press, Kent, UK, pp.: 37-52.
37. Olanow, C.W., Kordower, J.H. and Freeman, T.B. (1996): Fetal nigral transplantation as a therapy for Parkinson's disease. Trends in Neurosci., 19, 102-109.
38. Pezzoli, G., Canesi, M., Antonini, A., Righini, A., Perbellini, L., Barichella, M., Mariani, C.B., Tenconi, F., Tesei, S., Zecchinelli, A. and Leenders, K.L. (2000): Hydrocarbon exposure and Parkinson's disease. Neurology, 55, 667-673.
39. Piccini, P., Morrish, P.K. and Turjanski, N. (1997): Dopaminergic function in familial Parkinson's disease: a clinical and 18F-dopa positron emission tomography study. Ann. Neurol., 41, 222-229.
40. Pollanen, M.S., Dickson, D.W. and Bergeron, C. (1993): Pathology and biology of the Lewy body. J. Neuropathol. Exp. Neurol., 52, 183-191.
41. Polymeropoulos, M.H., Lavedan, C., Leroy, E., Ide, S.E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., Stenroos, E.S., Chandrasekharappa, S., Athanassiadou, A., Papapetropoulos, T., Johnson, W.G., Lazzarini, A.M., Duvoisin, R.C., Di Iorio, G., Golbe, L.I. and Nussbaum, R.L. (1997): Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science, 276, 2045-2047.
42. Quigley, E.M.M. (1996): Epidemiology and pathophysiology of gastrointestinal manifestations in Parkinson's disease. In: Corazziari, E. (ed.): Neurogastroenterology. pp.: 167-178., W. De Gruyter, Berlin.
43. Quinn, N. (1995): Parkinsonism-recognition and differential diagnosis. Brit. Med. J., 310, 447-452.
44. Ross, G.W., Abbott, R.D., Petrovitch, H., Morens, D.M., Grandinetti, A., Tung, K.H., Tanner, C.M., Masaki, K.H., Blanchette, P.L., Curb, J.D., Popper, J.S. and White, L.R. (2000): Association of coffee and caffeine intake with the risk of Parkinson disease. J. Am. Med. Assoc., 283, 2674-2679.
45. Semchuk, K.M, Love, E.J. and Lee, R.G. (1992): Parkinson's disease and exposure to agricultural work and pesticide chemicals. Neurology, 42, 1328-1335.
46. Starkstein, S.E., Mayberg, H.S., Leiguarda, R., Preziosi, T. and Robinson, R.G. (1992): A prospective longitudinal study of depression, cognitive decline, and physical impairments in patients with Parkinson's disease. J. Neurol. Neurosurg. Psychiatry, 55, 377-382.
47. Tison, F., Dartigues, J.F., Auriacombe, S., Letenneur, L., Boller, F. And Alperovitch, A. (1995): Dementia in Parkinson's disease: a population-based study in ambulatory and institutionalized individuals. Neurology, 45, 705-708.
48. Troster, A,I., Paolo, A.M., Lyons, K.E., Glatt, S.L., Hubble, J.P. and Koller, W.C. (1995): The influence of depression on cognition in Parkinson's disease: a pattern of impairment distinguishable from Alzheimer's disease. Neurology, 45, 672-676.
49. Valente, E.M., Brancati, F., Ferraris, A., Graham, E.A., Davis, M.B., Breteler, M.M., Gasser, T., Bonofati, V., Bentivoglio, A.R., De Michele, G., Durr, A., Cortelli, P., Wassilowsky, D., Harhangi, B.S., Rawal, N., Caputo, V., Filla, A., Meco, G., Oostra, B.A., Brice, A., Albanese, A. Dallapiccola, B. and Wood, N.W. (The European Consortium on Genetic Susceptibility of Parkinson's Disease). (2002): PARK6-linked parkinsonism occurs in several European families. Ann. Neurol., 51, 14-18.
50. Vescovi, A.L., Galli, R. and Gritti, A. (2001): The neural stem cell and their transdifferentation capacity. Biomed. Pharmacother., 55, 201-205.